トランスサイレチンアミロイドーシス転帰調査（THAOS）

基本情報

NCT ID

NCT00628745

ステータス

完了

試験のフェーズ

-

試験タイプ

観察

目標被験者数

6,718

治験依頼者名

Pfizer

概要

THAOS is a global, multi-center, longitudinal observational survey open to all patients with transthyretin amyloidosis (ATTR), including ATTR-PN (polyneuropathy), ATTR-CM (cardiomyopathy) and wild-type ATTR-CM. It is open-ended with a minimum duration of 10 years. Patients will be followed as long as they are able to participate. The principal aims of this outcome survey are to better understand and characterize the natural history of the disease by studying a large and heterogenous patient population. Survey data may be used to develop new treatment guidelines and recommendations, and to inform and educate clinicians about the management of this disease.

対象疾患

介入

依頼者（Sponsor）

実施施設 (3)